神经元α-突触核蛋白病的生物学定义:迈向整合性研究分期系统
本文提出将帕金森病和路易体痴呆重新定义为神经元α-突触核蛋白病,基于脑脊液种子扩增试验检测病理性α-突触核蛋白,并建立NSD-ISS分期系统。该系统以S和D两个生物学锚点及功能损害程度分层,目前仅用于研究。
要点
- 帕金森病和路易体痴呆应基于生物学标志物重新定义为神经元α-突触核蛋白病。
- NSD-ISS分期系统基于S和D两个生物学锚点及功能损害程度。
- NSD-ISS目前仅用于研究,临床应用尚不成熟且不合适。
核心结论
- 鉴于生物标志物进展,应将帕金森病和路易体痴呆重新定义为神经元α-突触核蛋白病而非临床综合征。
研究设计与样本
- 本文为提出生物学定义和分期系统的观点性文章,未报告系统检索方法或样本量。
主要发现
- 神经元α-突触核蛋白病由体内检测到病理性n-αsyn(S)定义,无论是否存在特定临床综合征。
- 存在病理性n-αsyn聚集的个体有多巴胺能神经元功能障碍(D)的风险。
- NSD-ISS分期中0-1期无体征或症状,2期有轻微体征或症状但无功能损害,2B-6期需S和D及阶段特异性功能损害增加。
- 生物学定义和NSD-ISS研究框架对早期疾病阶段的干预试验至关重要。
关键数值与推荐
- 0期由SNCA基因致病变异定义,1A期由S单独定义,1B期由S和D定义。
- 2期以临床表现为标志,有轻微体征或症状但无功能损害。
- 2B-6期需要S和D以及阶段特异性功能损害增加。
临床怎么用
- NSD-ISS目前仅用于研究,临床应用尚不成熟且不合适。
局限性
- NSD-ISS将随着数据驱动的阶段特异性功能锚点和额外生物标志物的出现和验证而演变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Parkinson's disease and dementia with Lewy bodies are currently defined by their clinical features, with α-synuclein pathology as the gold standard to establish the definitive diagnosis. We propose that, given biomarker advances enabling accurate detection of pathological α-synuclein (ie, misfolded and aggregated) in CSF using the seed amplification assay, it is time to redefine Parkinson's disease and dementia with Lewy bodies as neuronal α-synuclein disease rather than as clinical syndromes. This major shift from a clinical to a biological definition of Parkinson's disease and dementia with Lewy bodies takes advantage of the availability of tools to assess the gold standard for diagnosis of neuronal α-synuclein (n-αsyn) in human beings during life. Neuronal α-synuclein disease is defined by the presence of pathological n-αsyn species detected in vivo (S; the first biological anchor) regardless of the presence of any specific clinical syndrome. On the basis of this definition, we propose that individuals with pathological n-αsyn aggregates are at risk for dopaminergic neuronal dysfunction (D; the second biological anchor). Our biological definition establishes a staging system, the neuronal α-synuclein disease integrated staging system (NSD-ISS), rooted in the biological anchors (S and D) and the degree of functional impairment caused by clinical signs or symptoms. Stages 0-1 occur without signs or symptoms and are defined by the presence of pathogenic variants in the SNCA gene (stage 0), S alone (stage 1A), or S and D (stage 1B). The presence of clinical manifestations marks the transition to stage 2 and beyond. Stage 2 is characterised by subtle signs or symptoms but without functional impairment. Stages 2B-6 require both S and D and stage-specific increases in functional impairment. A biological definition of neuronal α-synuclein disease and an NSD-ISS research framework are essential to enable interventional trials at early disease stages. The NSD-ISS will evolve to include the incorporation of data-driven definitions of stage-specific functional anchors and additional biomarkers as they emerge and are validated. Presently, the NSD-ISS is intended for research use only; its application in the clinical setting is premature and inappropriate.
引用
- Simuni T, Chahine LM, Poston K, et al. A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research. Lancet Neurol. 2024. PMID: 38267190. doi:10.1016/S1474-4422(23)00405-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。